- Home
- TRVI vs XPEL Comparison
TRVI vs XPEL Comparison
Compare TRVI & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- XPEL
- Stock Information
- Founded
- TRVI 2011
- XPEL 1999
- Country
- TRVI United States
- XPEL United States
- Employees
- TRVI N/A
- XPEL N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- XPEL Industrial Specialties
- Sector
- TRVI Health Care
- XPEL Industrials
- Exchange
- TRVI Nasdaq
- XPEL Nasdaq
- Market Cap
- TRVI 1.1B
- XPEL 984.3M
- IPO Year
- TRVI 2019
- XPEL N/A
- Fundamental
- Price
- TRVI $9.64
- XPEL $34.03
- Analyst Decision
- TRVI Strong Buy
- XPEL
- Analyst Count
- TRVI 9
- XPEL 0
- Target Price
- TRVI $20.72
- XPEL N/A
- AVG Volume (30 Days)
- TRVI 2.6M
- XPEL 289.6K
- Earning Date
- TRVI 11-05-2025
- XPEL 11-06-2025
- Dividend Yield
- TRVI N/A
- XPEL N/A
- EPS Growth
- TRVI N/A
- XPEL 2.75
- EPS
- TRVI N/A
- XPEL 1.76
- Revenue
- TRVI N/A
- XPEL $448,897,000.00
- Revenue This Year
- TRVI N/A
- XPEL $12.54
- Revenue Next Year
- TRVI N/A
- XPEL $10.52
- P/E Ratio
- TRVI N/A
- XPEL $19.22
- Revenue Growth
- TRVI N/A
- XPEL 9.96
- 52 Week Low
- TRVI $2.36
- XPEL $24.25
- 52 Week High
- TRVI $10.16
- XPEL $47.23
- Technical
- Relative Strength Index (RSI)
- TRVI 64.43
- XPEL 47.81
- Support Level
- TRVI $8.24
- XPEL $31.87
- Resistance Level
- TRVI $8.65
- XPEL $35.02
- Average True Range (ATR)
- TRVI 0.51
- XPEL 1.11
- MACD
- TRVI 0.10
- XPEL 0.17
- Stochastic Oscillator
- TRVI 76.06
- XPEL 66.86
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.